CAR-T therapy, a “sky-high priced cancer treatment,” may see a breakthrough in commercial insurance pricing negotiations this year.
November 3, 2025
Source: drugdu
77
At approximately 3 PM today, during the on-site negotiations for the 2025 National Reimbursement Drug List and the discussion on innovative drugs covered by commercial insurance...At the price negotiation meeting, representatives from HeYuan Biotech, unable to hide their joy after concluding price negotiations, told reporters from Cailian Press, "We've reached an agreement," but the final result will still be subject to the final announcement by the National Healthcare Security Administration. This means that CAR-T drugs, including HeYuan Biotech's Nakiorenzai injection, are expected to achieve a breakthrough in this year's price negotiations for innovative drugs covered by commercial insurance. HeYuan Biotech's Nakiorenzai injection was approved for marketing in 2023, and five CAR-T drugs, represented by Nakiorenzai, have all passed the preliminary review for the innovative drug list covered by commercial insurance this year. Due to its high price, CAR-T therapy has failed to enter the "threshold" of national medical insurance negotiations for the past four years.
Source: https://finance.eastmoney.com/a/202511023552696722.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
